Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2011 2
2012 2
2015 1
2016 1
2017 1
2018 1
2022 1
2023 1
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean ju lian cai[Author] (1 results)?
Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma.
Mei M, Palmer J, Tsai NN, Simpson J, O'Hearn J, Stein A, Forman S, Spielberger R, Cai JL, Htut M, Nakamura R, Al Malki MM, Herrera A, Wong J, Nademanee A. Mei M, et al. Among authors: cai jl. Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):e268-e276. doi: 10.1016/j.clml.2023.05.011. Epub 2023 May 23. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37301631 Clinical Trial.
Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study.
Ali H, Tsai NC, Synold T, Mokhtari S, Tsia W, Palmer J, Stiller T, Al Malki M, Aldoss I, Salhotra A, Rahmanuddin S, Pullarkat V, Cai JL, Stein A, Forman SJ, Marcucci G, Mei M, Snyder DS, Nakamura R. Ali H, et al. Among authors: cai jl. Blood Adv. 2022 Mar 8;6(5):1444-1453. doi: 10.1182/bloodadvances.2021005035. Blood Adv. 2022. PMID: 34581764 Free PMC article.
Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis.
Nakamura R, Palmer JM, O'Donnell MR, Stiller T, Thomas SH, Chao J, Alvarnas J, Parker PM, Pullarkat V, Maegawa R, Stein AS, Snyder DS, Bhatia R, Chang K, Wang S, Cai JL, Senitzer D, Forman SJ. Nakamura R, et al. Among authors: cai jl. Leuk Res. 2012 Sep;36(9):1152-6. doi: 10.1016/j.leukres.2012.04.022. Epub 2012 Jun 5. Leuk Res. 2012. PMID: 22677229 Free PMC article.
Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Othman T, Koller P, Pourhassan H, Agrawal V, Ngo D, Tinajero J, Ali H, Cai JL, Mei M, Aribi A, Stein AS, Marcucci G, Forman SJ, Pullarkat V, Aldoss I. Othman T, et al. Among authors: cai jl. Br J Haematol. 2024 May 29. doi: 10.1111/bjh.19551. Online ahead of print. Br J Haematol. 2024. PMID: 38808512 No abstract available.
Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.
Chen RW, Palmer JM, Tomassetti S, Popplewell LL, Alluin J, Chomchan P, Nademanee AP, Siddiqi T, Tsai NC, Chen L, Zuo F, Abary R, Cai JL, Herrera AF, Rossi JJ, Rosen ST, Forman SJ, Kwak LW, Holmberg LA. Chen RW, et al. Among authors: cai jl. J Hematol Oncol. 2018 Jun 28;11(1):87. doi: 10.1186/s13045-018-0631-3. J Hematol Oncol. 2018. PMID: 29954415 Free PMC article. Clinical Trial.
Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma.
Othman T, Baird JH, Pak S, Mei M, Herrera AF, Mansour J, Shouse G, Sahebi F, Spielberger R, Cai JL, Farol L, Godfrey J, Kallam A, Phillips T, Popplewell L, Siddiqi T, Forman S, Budde LE. Othman T, et al. Among authors: cai jl. Br J Haematol. 2024 May 26. doi: 10.1111/bjh.19521. Online ahead of print. Br J Haematol. 2024. PMID: 38797530 No abstract available.
Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Othman T, Koller P, Tsai NC, Yang D, Pourhassan H, Agrawal V, Ngo D, Chen J, Farol L, Spielberger R, Sahebi F, Al Malki MM, Cai JL, Sandhu KS, Mansour J, Salhotra A, Ali H, Aribi A, Arslan S, Marcucci G, Forman SJ, Stein AS, Nakamura R, Pullarkat V, Aldoss I, Mei M. Othman T, et al. Among authors: cai jl. Am J Hematol. 2024 May 28. doi: 10.1002/ajh.27378. Online ahead of print. Am J Hematol. 2024. PMID: 38804599
Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.
Mei MG, Cao TM, Chen L, Song JY, Siddiqi T, Cai JL, Farol LT, Al Malki MM, Salhotra A, Aldoss I, Palmer J, Herrera AF, Zain J, Popplewell LL, Chen RW, Rosen ST, Forman SJ, Kwak L, Nademanee AP, Budde LE. Mei MG, et al. Among authors: cai jl. Biol Blood Marrow Transplant. 2017 Nov;23(11):1861-1869. doi: 10.1016/j.bbmt.2017.07.006. Epub 2017 Jul 18. Biol Blood Marrow Transplant. 2017. PMID: 28733266 Free PMC article.
Phase 1 Study of Bortezomib, Fludarabine, and Melphalan, With or Without Total Marrow Irradiation, as Allogeneic Hematopoietic Stem Cell Transplant Conditioning for High-risk or Relapsed/Refractory Multiple Myeloma.
Ladbury C, Sanchez J, Chowdhury A, Palmer J, Liu A, Stein A, Htut M, Farol L, Cai JL, Somlo G, Rosenzweig M, Wong JC, Sahebi F. Ladbury C, et al. Among authors: cai jl. Am J Clin Oncol. 2024 Mar 14. doi: 10.1097/COC.0000000000001095. Online ahead of print. Am J Clin Oncol. 2024. PMID: 38483213
13 results